

## Research Paper

# Median Effective Dose of Dexmedetomidine Inducing Bradycardia in Elderly Patients Determined by Up-and-Down Sequential Allocation Method

Hua Yang, MD<sup>1\*</sup>; Yu Fu, MD<sup>2\*</sup>; Fang Deng, MD<sup>1\*</sup>; Yun Shao, MD<sup>1</sup>; Yu-Gang Lu, MD<sup>2</sup>✉, Jin-Chao Song, MD<sup>1</sup>✉

1. Department of Anesthesiology, Shidong Hospital Affiliated to University of Shanghai for Science and Technology, Shanghai, China.
2. Department of Anesthesiology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.

\*These authors contributed equally to this work.

✉ Corresponding authors: **Jin-Chao Song**, M.D. Department of Anesthesiology, Shidong Hospital of Shanghai, University of Shanghai for Science and Technology, Shiguang Road, No. 999 Shanghai, China. Phone: (86) 21-25066782. E-mail: sjch2013@163.com; **Yu-Gang Lu**, M.D. Department of Anesthesiology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, China. E-mail: luyugang@tongji.edu.cn.

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>). See <http://ivyspring.com/terms> for full terms and conditions.

Received: 2022.01.24; Accepted: 2022.05.15; Published: 2022.06.13

## Abstract

**Purpose:** When dexmedetomidine is used in elderly patients, high incidence of bradycardia is reported. Given age-related physiological changes in this population, it is necessary to know the safety margin between the loading dose of dexmedetomidine and bradycardia. Therefore, we conducted this study to investigate the median effective dose (ED<sub>50</sub>) of dexmedetomidine causing bradycardia in elderly patients.

**Methods:** Thirty patients with ages over 65 years undergoing elective general surgery were enrolled. The Dixon and Massay sequential method were applied to determine the loading dose of dexmedetomidine, starting from 1.0 µg/kg. The dose for the follow-up subjects increased or decreased according to the geometric sequence with the common ratio 1.2, based on the 'negative' or 'positive' response of the previous subject. Positive mean that the subject developed bradycardia during the test. Hemodynamic data including heart rate and systolic blood pressure were recorded. The level of sedation was assessed with the Observer Assessment of Alertness and Sedation Scale (OAA/S).

**Results:** Bradycardia occurred in 13 patients (43.3%). The ED<sub>50</sub> of dexmedetomidine causing bradycardia was 1.97 µg/kg (95% CI, 1.53–2.53 µg/kg). OAA/S scores at 10 min after the beginning of the dexmedetomidine infusion and 10 min after the termination of dexmedetomidine administration showed no significant differences between the positive and negative groups ( $P > 0.05$ ).

**Conclusion:** The ED<sub>50</sub> of dexmedetomidine causing bradycardia in our cohort was higher than clinical recommended dose. A higher loading dose appears acceptable for a faster onset of sedation under careful hemodynamic monitoring.

**Trial registration:** ChiCTR15006368.

Key words: dexmedetomidine, bradycardia, elderly patient, intravenous anaesthesia, adverse effects

## Introduction

Dexmedetomidine is a potent and highly selective  $\alpha_2$ -adrenoceptor agonist displaying anxiolytic, sedative, sympatholytic, and analgesic effects with minimum cardiovascular and respiratory depression [1]. Neurophysiologically, sedation using dexmedetomidine approximates stage 2 non-rapid eye movement sleep and reduces the incidence of delirium [2-4]. Moreover, the administration of dexmedetomidine during operation is linked with a reduction in the incidence of postoperative shivering,

nausea and vomiting [5]. Aside from all the advantages, dexmedetomidine also has its shortcomings, the most crucial of which are bradycardia and even, in rare cases, cardiac arrest, especially for elderly patients [6-10]. A higher incidence of bradycardia in patients aged older than 65 years was reported by the registration documents of the European Medicines Agency and the US Food and Drug Administration [11].

The cardiovascular effects of dexmedetomidine begin with transitory hypertension after the administration of a loading dose, owing to the activation of  $\alpha_2B$  receptors, with consequent hypotension and bradycardia because of the reduction of sympathetic tone [12, 13]. Specially, an upper dose of dexmedetomidine has more profound influence on hemodynamic parameters in elderly patients, and though the pharmacokinetic profile of dexmedetomidine was not altered by age [14]. Thus, age-related physiological changes must be considered when administering intravenous dexmedetomidine to elderly patients.

The hemodynamic effects of dexmedetomidine after short-term (2, 5 or 10 min) infusions have been described and summarized at doses ranged from 0.25 to 4  $\mu\text{g}/\text{kg}$  [15]. It is known that dexmedetomidine had a significant dose-response relationship with bradycardia. However, the median effective dose (ED50) of intravenous dexmedetomidine conducting significant bradycardia in elderly patients remains undetermined.

The aim of this study was to determine the ED50 values of intravenous dexmedetomidine causing bradycardia in elderly patients (aged >65 years) by Dixon's up-and-down sequential allocation method.

## Materials and Methods

### Study design and patients

This study was approved by the Institutional Research Ethics Committee of Shidong Hospital Affiliated to University of Shanghai for Science and Technology. The trial was registered at Chinese Clinical Trial Registry (ChiCTR 15006368). Patients aged 65 years and over scheduled for general surgery under general anesthesia were considered eligible. Patients were excluded if they: (1) American Society of Anesthesiologists (ASA) physical status score  $\geq 3$ , (2) allergies to any of the drugs used for anesthesia, (3) body mass index (BMI)  $\leq 20$  or  $\geq 30$   $\text{kg}/\text{m}^2$ , (4) taking hypnotics, opioid analgesic or antianxiety agents, (5) known or suspected heart failure (ejection fraction  $< 40\%$ ), severe respiratory disease, renal or metabolic diseases, (6) heart rate (HR)  $< 60$  bpm, sick sinus syndrome, atrioventricular block, arrhythmia or atrial fibrillation, (7) electrolyte disturbances, (8) could not complete the informed consent procedure independently. A total of 30 elderly patients undergoing general surgery from July to August in 2020 were enrolled in the study and written informed consent was obtained from each patient.

### Preoperative preparations and anesthesia protocol

After overnight fasting, the patients without any pre-medication were brought to a quiet operating room where a 20-gauge intravenous cannula was placed in the peripheral vein for Ringer's lactate solution at 15-18  $\text{ml}/\text{kg}/\text{h}$ . All patients were monitored with electrocardiogram (ECG), HR, pulse oximetry ( $\text{SpO}_2$ ), and non-invasive blood pressure (BP).

The dexmedetomidine (Dexmedetomidine Hydrochloride Injection, 2 ml: 200  $\mu\text{g}$ , Jiangsu Hengrui Pharmaceutical Co., Ltd.), diluted in 50 ml of saline 0.9% and delivered at an assigned rate by a Graseby 3500 syringe pump (SIMS Graseby Ltd., Herts, UK). The first patient was tested at a loading dose of 1.0  $\mu\text{g}/\text{kg}$  in 10 min without maintenance dose, which was the recommended loading dose according to the instructions for dexmedetomidine. The dose for the follow-up subjects was determined by the response of the previous patient, using the modified Dixon's up-and-down method [16]. The response of the patients was categorized as either 'negative' or 'positive'. Negative mean the patient did not develop bradycardia throughout the trial. Positive mean that the patient developed bradycardia during the test. The dose of dexmedetomidine for the next patient would be reduced if the previous patient had a positive result. On the contrary, the dose of dexmedetomidine for the next patient would be increased accordingly. The dose for the next subject increased or decreased step by step according to the geometric sequence with the common ratio 1.2. If the bradycardia occurs during the infusion of dexmedetomidine, the procedure was discontinued, and in case of persistence of severe bradycardia and/or accompanied by hypotension, a bolus of intravenous atropine 0.5 mg plus 200 ml of intravenous Ringer's lactate solution was administered. Oxygen was administered at a flow of 5 L/min by a nasal catheter during the study.

During 10 minutes after the termination of loading dose of dexmedetomidine infusion, early signs of hypotension, hypertension, bradycardia, respiratory depression, airway obstruction, apnoea, dyspnoea and/or oxygen desaturation were monitored continuously. At 10 minutes after the termination of the loading dose of dexmedetomidine administration, anaesthesia was induced with propofol (0.7-1.0  $\text{mg}/\text{kg}$ ), cisatracurium (0.2  $\text{mg}/\text{kg}$ ) and sufentanil (0.4-0.5  $\mu\text{g}/\text{kg}$ ). Endotracheal intubation was performed and mechanical ventilation began. Anesthesia maintenance was provided by sevoflurane.

## Measurements

The baseline ( $T_0$ ) of BP and HR were defined as the average of three consecutive measurements at the time when patients arrived in the operating room with supine position. Haemodynamic data were also measured at 3 min ( $T_1$ ), 6 min ( $T_2$ ) and 10 min ( $T_3$ ) after the beginning of the dexmedetomidine infusion, 3min ( $T_4$ ), 6 min ( $T_5$ ) and 10 min ( $T_6$ ) after the termination of dexmedetomidine administration and immediately before anesthesia induction ( $T_7$ ). Bradycardia was defined as HR less than 50 beats/min. Hypotension was defined as decrease in systolic blood pressure by more than 30% of the baseline value. Hypertension is defined as an increase in systolic blood pressure more than 30% of the baseline value. Other types of arrhythmia and hypoxemia were also recorded. The level of sedation was assessed at  $T_3$  and  $T_6$  using the Observer Assessment of Alertness and Sedation Scale (OAA/S) score [17].

## Statistical analysis

Owing to the characteristic of the up-and-down sequential method, the sample size was determined by the results of simulation study suggesting that 20-40 patients will provide stable estimate of ED50. Thus, a total of 30 patients were determined in this study. ED50 was estimated from the up-and-down sequences, using the modified Dixon's up-and-down method. The dosage of ED50 was determined from the midpoints of all independent pairs of patients who involve a crossover from 'negative' response to 'positive' response.

All statistical analyses were performed using SPSS, version 20.0 (SPSS Inc., Chicago, IL, USA). Data are expressed as mean (standard deviation, SD) for continuous variables, frequency (percentage) for categorical variables, or median (interquartile range, IQR) for continuous variables with skewed distribution, as appropriate. Nominal data were analyzed using the Chi-square test, normally distributed continuous data were analyzed using Student's t-test and non-normally distributed continuous data were analyzed using nonparametric Mann Whitney U test. For within-group comparison, the repeated-measures ANOVA with adjustment for multiple comparisons to control the type I error with Bonferroni test was used for normal data. Statistical significance was defined as  $P < 0.05$ .

## Results

The study flow diagram is presented in Fig. 1. The study was stopped after the enrolment of 30 consecutive patients. Patients' characteristics are

presented in Table 1.

**Table 1.** Baseline characteristics of the patients

	Positive (n=13)	Negative (n=17)	P-value
Age, yr	73.5±6.4	74.1±8.2	0.836
Gender, male/female	8/5	10/7	0.880
Height, cm	169.0±7.6	163.5±8.5	0.077
BMI, kg/m <sup>2</sup>	23.1±2.7	23.4±3.9	0.776
ASA, I/II	8/5	11/6	0.858
Albumin, g/L	39.8±4.8	38.2±4.3	0.325
Bilirubin, µmol/L	16.0±6.2	14.3±5.4	0.441
ALT, U/L	28.2±13.7	21.8±20.7	0.342
AST, U/L	28.5±11.6	27.4±37.8	0.914
SCR, mmol/l	69.4±12.5	78.7±38.9	0.367
BUN, mmol/l	5.0±1.6	5.4±2.0	0.534
Baseline SBP, mmHg	147.8±20.1	148.1±16.1	0.968
Baseline HR, beats/min	66.9±5.2	70.5±5.1	0.075

Data are shown as mean ± SD.

BMI, body mass index; ASA, American Society of Anesthesiologists; ALT, alanine aminotransferase; AST, aspartate aminotransferase; SCR, serum creatinine, BUN, blood urea nitrogen; SBP, systolic blood pressure; HR, heart rate.

P value in Student's t-test, or  $\chi^2$  test.

The defined positive outcomes took place in 13 patients, 11 of which had positive results during the dexmedetomidine infusion, and 2 of which had positive results after the infusion within 10 minutes. There was no significant difference in demographic data between the positive and negative groups ( $P > 0.05$ ).

The sequence of the dose of dexmedetomidine is illustrated in Fig. 2. There were 8 pairs of reversal of sequence in this study, which showed that our sample size was enough. The assigned dexmedetomidine were 0.83 µg/kg, 1.0 µg/kg, 1.2 µg/kg, 1.44 µg/kg, 1.73 µg/kg, 2.08 µg/kg, 2.5 µg/kg, 3.0 µg/kg and 3.6 µg/kg. The ED50 of dexmedetomidine inducing bradycardia, by Dixon and Massay up-down sequential method, was 1.97 µg/kg (95% CI, 1.53–2.53 µg/kg) (Fig. 2). The percentages of different doses of dexmedetomidine inducing bradycardia are shown in Fig. 3.

OAA/S scores at  $T_3$  and  $T_6$  showed no significant differences between the 2 groups ( $P > 0.05$ ). After dexmedetomidine administration, OAA/S scores of both groups at  $T_6$  were lower than those at  $T_3$  ( $P < 0.05$ ) (Table 2).

**Table 2.** Comparison of OAA/S score at  $T_3$  and  $T_6$  time points

	Positive (n=13)	Negative (n=17)	P-value
OAA/S score			
$T_3$	5 (3.5, 5)	4 (2.5, 5)	0.503
$T_6$	2 (2, 3)*	3 (2, 4)*	0.122

Data are presented as median (25th percentile, 75th percentile). OAA/S, Observer's Assessment of Alertness and Sedation Scale. \* $P < 0.05$  compared with the same group at  $T_3$ .




Figure 1. Flowchart of patients enrolled in the study.




Figure 2. Consecutive dose of dexmedetomidine for ED50 determination. A positive dose is denoted by a solid circle; a negative dose is denoted by an open circle. Dexmedetomidine ED50 causing significant bradycardia was 1.97  $\mu\text{g}/\text{kg}$  (95% confidence interval 1.53–2.53  $\mu\text{g}/\text{kg}$ ) calculated by Dixon and Massay formula.





Figure 3. The percentage of bradycardia or no bradycardia at different doses of dexmedetomidine.



**Figure 4. The heart rate and systolic blood pressure in positive and negative groups. (A)** The heart rate at different times in the two groups. **(B)** The systolic blood pressure at different times in the two groups. Baseline: Before infusing the dexmedetomidine. \* $P < 0.05$  compared between groups in the same period. # $P < 0.05$  vs baseline within group.

The HRs were similar in all two groups at baseline (Fig. 4A). However, negative group showed significant increase in HR than positive group at T<sub>1-7</sub> ( $P < 0.05$ ). In addition, Comparing HR to baseline within positive group, HR was significantly lower at T<sub>1-7</sub> ( $P < 0.05$ ). Comparing HR to baseline within negative group, HR was only significantly lower at T<sub>3</sub> ( $P < 0.05$ ). Data regarding SBP are shown in Fig. 4B. SBP showed no significant difference in each comparison at the same period between the groups ( $P > 0.05$ ). Comparing SBP to baseline within both groups, there were also no significant difference at each time point ( $P > 0.05$ ).

The study was completed without any significant clinical complication. No episode of hypotension (systolic blood pressure decrease of 30% the baseline value), hypoxemia, or respiratory depression occurred during the study. The systolic blood pressure increased over 200 mmHg in 2 patients, but they were under 30% the baseline value. No patients needed atropine or ephedrine.

## Discussion

Bradycardia is a common adverse reaction of dexmedetomidine, which incidence varying from 10% to 30% depending on the dose of dexmedetomidine [15, 18]. Age-adjusted dosing is not recommended,

although caution is warranted as hemodynamic effect might be more pronounced in elderly patients [14]. Previous studies [19] suggested that dexmedetomidine plays a valuable role in the multimodal administration of nonopioid agents which can reach the intraoperative hemodynamic stability and the antinociception traditionally obtained by opioids. However, the dose of dexmedetomidine is used for this purpose may promote risk of bradycardia during surgery [20].

It is likely that a lower dose might have prevented such an event, but which may not achieve the level of sedation required. For sedation in the operating room, a faster onset of effect from dexmedetomidine is often desired such as awake fiberoptic intubation [21], awake craniotomies [22], or rescue sedation under certain scenario [17]. A loading dose of dexmedetomidine has been routinely administrated to gain a faster onset of effect and mitigate side effects by which infused over 10 minutes. To the best of our knowledge, the ED<sub>50</sub> of intravenous dexmedetomidine conducting significant bradycardia in elderly patients (aged >65 years) remains undetermined.

The first question in this study sought to determine the ED<sub>50</sub> values of intravenous dexmedetomidine causing bradycardia in elderly

patients (aged >65 years). Studies have shown that loading doses of 0.5-1.0 µg/kg dexmedetomidine in 10 min, followed by an infusion at a rate of 0.2-0.7 µg/kg/h, provide effective sedation and be well-tolerated for elderly patients [23, 24]. In this randomized up-down sequential allocation study, we found that the ED50 of intravenous dexmedetomidine causing bradycardia in elderly patients was 1.97 µg/kg (95% CI, 1.53-2.53 µg/kg). It has to be said that this is one unanticipated finding, which well above a loading dose of 1 µg/kg in 10 min that is recommended [14]. What's more, when taking into account the possible effects of age-related physiological changes in elderly patients, a loading dose of like this in geriatric patients is not suggested. If a faster onset of sedation is needed, a slightly higher loading dose appears to be accepted for these patients under close supervision.

In the current study, the observation and recording of bradycardia is set before anesthesia induction, which advantage is the absence of other pharmacologic confounding factors, such as opioids and sevoflurane may have played the synergistic roles with dexmedetomidine. Previous studies [25] showed that the peak of HR decrease appeared at 3 minutes and carried on 11 minutes after infusing 0.25 µg/kg to 2.0 µg/kg of dexmedetomidine over 2 minutes in healthy adult volunteers. These changes were similar to our findings. In this study, 13 patients experienced bradycardia, 11 of which had positive results during the dexmedetomidine infusion, which was treated with suspending the infusion. Fortunately, no patients needed atropine or ephedrine throughout this study. In addition, the negative chronotropic properties of dexmedetomidine are well enough acknowledged that a clinical trial even describes the controlled hypotension use of dexmedetomidine during rhinoplasty [26]. However, it is a nerve-racking job to reduce the incidence of bradycardia while the hypotensive effect is preserved. The result of our study, therefore, has certain value in promoting the clinical application of dexmedetomidine.

Dexmedetomidine exerts sedative and anti-anxiety effects since acting on central pre- and postsynaptic α<sub>2</sub>-receptors in the locus coeruleus. After sedation, dexmedetomidine may also induce physiological sleep without obvious respiratory suppression [27]. In this study, we observed similar levels of sedation between the two groups at 10 min after the termination of dexmedetomidine administration, which similar to the findings of Gu et al. [28] on the time to sedation.

Dexmedetomidine produces a typical biphasic effect on blood pressure, a transient increase followed by a longer lasting decrease in blood pressure [14]. We

also observed this biphasic response in SBP before anesthesia induction. This was thought to activation of α<sub>2</sub>-receptor in the vascular smooth muscles, leading peripheral vasoconstriction and consequently hypertension. After a few minutes, the vasodilatation, presynaptic α<sub>2</sub>-adrenoreceptors inhibiting sympathetic release of catecholamines and the increased vagal activity, causing a hypotensive phase [29]. Although the systolic blood pressure increased over 200 mmHg in 2 patients, the maximum changes in hemodynamics were all less than 30% of the baseline, which is generally considered acceptable.

Generally speaking, this study was an exploratory trial under the safety of all patients. All subjects had normal liver and kidney function without co-morbidities before enrollment. During dexmedetomidine infusion, all patients had continuous cardiac and respiration monitoring. In addition, the trial was conducted under the close supervision of experienced doctors. Finally, all subjects did not suffer further sequelae related to the dexmedetomidine in the recovery and postoperative periods.

There were several limitations in the current study. First, we did not record the hemodynamics data after anesthesia induction, which could be theoretically influenced by dexmedetomidine. Second, sedation in this study was only measured subjectively using OAA/S, lacking the bispectral index (BIS) monitoring during the infusion of dexmedetomidine. Third, the up-and-down method was used to determine the ED50 in the current study, which premise is that the dose-effect relationship is the traditional S-shaped curve, and often depended on a small sample size. But this did not provide reliable insight into the upper tail of the distribution, which may be imprecise [16]. Besides, this study was launched in relatively healthy patients (normal renal and hepatic function) as well as these patients were not receiving any other common vasoactive agents (such as beta-blockers, calcium channel blockers, etc.) that might potentiate the hemodynamic effect of dexmedetomidine. This alleviates the generalization of these results to common practice. Additional studies, that different dexmedetomidine loading doses in different disease settings, are needed.

In conclusion, the ED50 of intravenous dexmedetomidine causing bradycardia in elderly patients was 1.97 µg/kg. A slightly higher loading dose appears to be accepted for a faster onset of sedation under careful hemodynamic monitoring. Moreover, the use of dexmedetomidine during daily practice should be cautiously evaluated for each patient.

## Abbreviations

ED50: median effective dose; ASA: American Society of Anesthesiologists; BMI: body mass index; HR: heart rate; ECG: electrocardiogram; BP: blood pressure; OAA/S: Observer Assessment of Alertness and Sedation Scale; BIS: bispectral index.

## Acknowledgements

### Funding

This study was supported by the National Natural Science Foundation of China: (NSFC, No.81371511), The Science and Technology Commission and Health Committee of Yangpu District, Shanghai: (YPM202105), and the Yangpu District Good-Doctor Program.

### Author Contributions

Study design and governmental applications: Jin-Chao Song, Yu-Gang Lu. Patient recruitment, anaesthesia, and data collection: Hua Yang, Jin-Chao Song. Data analyses: Yu Fu, Yu-Gang Lu. Writing paper: All authors. Manuscript modification: Fang Deng, Yun Shao.

### Competing Interests

The authors have declared that no competing interest exists.

## References

1. Van Norden J, Spies CD, Borchers F, et al. The effect of perioperative dexmedetomidine on the incidence of postoperative delirium in cardiac and non-cardiac surgical patients: a randomised, double-blind placebo-controlled trial. *Anaesthesia*. 2021; 76: 1296-9.
2. Akeju O, Hobbs LE, Gao L, et al. Dexmedetomidine promotes biomimetic non-rapid eye movement stage 3 sleep in humans: A pilot study. *Clin Neurophysiol*. 2018; 129: 69-78.
3. Reade MC, Eastwood GM, Bellomo R, et al. Effect of Dexmedetomidine Added to Standard Care on Ventilator-Free Time in Patients with Agitated Delirium: A Randomized Clinical Trial. *JAMA*. 2016; 315: 1460-8.
4. Ramaswamy SM, Weerink MAS, Struys MMRF, et al. Dexmedetomidine-induced deep sedation mimics non-rapid eye movement stage 3 sleep: large-scale validation using machine learning. *Sleep*. 2021; 44: zsa1167.
5. Grape S, Kirkham KR, Frauenknecht J, et al. Intra-operative analgesia with remifentanyl vs. dexmedetomidine: a systematic review and meta-analysis with trial sequential analysis. *Anaesthesia*. 2019; 74: 793-800.
6. Hui C, Cardinale M, Yegneswaran B. Significant Bradycardia in Critically Ill Patients Receiving Dexmedetomidine and Fentanyl. *Case Rep Crit Care*. 2017; 2017: 450427.
7. Aikaterini A, Ioannis D, Dimitrios G; et al. Bradycardia Leading to Asystole Following Dexmedetomidine Infusion during Cataract Surgery: Dexmedetomidine-Induced Asystole for Cataract Surgery. *Case Rep Anaesthesiol*. 2018; 2018: 2896032.
8. Shehabi Y, Howe BD, Bellomo R, et al. Early Sedation with Dexmedetomidine in Critically Ill Patients. *N Engl J Med*. 2019; 380: 2506-17.
9. Tan JA, Ho KM. Use of dexmedetomidine as a sedative and analgesic agent in critically ill adult patients: a meta-analysis. *Intensive Care Med*. 2010; 36: 926-39.
10. Qin C, Jiang Y, Lin C, et al. Perioperative dexmedetomidine administration to prevent delirium in adults after non-cardiac surgery: A systematic review and meta-analysis. *J Clin Anesth*. 2021; 73: 110308.
11. Bohringer C, Liu H. Is It Time for an Expanded Role of Dexmedetomidine in Contemporary Anesthesia Practice? - A Clinician's Perspective. *Transl Perioper Pain Med*. 2018; 5: 55-62.
12. Ng KT, Shubash CJ, Chong JS. The effect of dexmedetomidine on delirium and agitation in patients in intensive care: systematic review and meta-analysis with trial sequential analysis. *Anaesthesia*. 2019; 74: 380-92.
13. Talke P, Anderson BJ. Pharmacokinetics and pharmacodynamics of dexmedetomidine-induced vasoconstriction in healthy volunteers. *Br J Clin Pharmacol*. 2018; 84: 1364-72.
14. Weerink MAS, Struys MMRF, Hannivoort LN, et al. Clinical Pharmacokinetics and Pharmacodynamics of Dexmedetomidine. *Clin Pharmacokinet*. 2017; 56: 893-913.
15. Colin PJ, Hannivoort LN, Eleveld DJ, et al. Dexmedetomidine pharmacodynamics in healthy volunteers: 2. Haemodynamic profile. *Br J Anaesth*. 2017; 119: 211-20.
16. Pace NL, Stylianou MP. Advances in and limitations of up-and-down methodology: a précis of clinical use, study design, and dose estimation in anesthesia research. *Anesthesiology*. 2007; 107: 144-52.
17. Zhang W, Fan Y, Zhao T, et al. Median Effective Dose of Intranasal Dexmedetomidine for Rescue Sedation in Pediatric Patients Undergoing Magnetic Resonance Imaging. *Anesthesiology*. 2016; 125: 1130-35.
18. Ahn EJ, Park JH, Kim HJ, et al. Anticholinergic premedication to prevent bradycardia in combined spinal anesthesia and dexmedetomidine sedation: a randomized, double-blind, placebo-controlled study. *J Clin Anesth*. 2016; 35:13-9.
19. Beloeil H, Garot M, Lebuffe G, et al. Balanced Opioid-free Anesthesia with Dexmedetomidine versus Balanced Anesthesia with Remifentanyl for Major or Intermediate Noncardiac Surgery. *Anesthesiology*. 2021; 134: 541-51.
20. De Cassai A, Boscolo A, Geraldini F, et al. Effect of dexmedetomidine on hemodynamic responses to tracheal intubation: A meta-analysis with meta-regression and trial sequential analysis. *J Clin Anesth*. 2021; 72: 110287.
21. He XY, Cao JP, He Q, et al. Dexmedetomidine for the management of awake fiberoptic intubation. *Cochrane Database Syst Rev*. 2014; 2014: CD009789.
22. Goettel N, Bharadwaj S, Venkatraghavan L, et al. Dexmedetomidine vs propofol-remifentanyl conscious sedation for awake craniotomy: a prospective randomized controlled trial. *Br J Anaesth*. 2016; 116: 811-21.
23. Kim J, Kim WO, Kim NB, et al. Effective dose of dexmedetomidine to induce adequate sedation in elderly patients under spinal anesthesia. *Korean J Anesthesiol*. 2015; 68: 575-80.
24. Wang C, Zhang H, Fu Q. Effective dose of dexmedetomidine as an adjuvant sedative to peripheral nerve blockade in elderly patients. *Acta Anaesthesiol Scand*. 2018; 62: 848-56.
25. Bloor BC, Ward DS, Belleville JP, et al. Effects of intravenous dexmedetomidine in humans. II. Hemodynamic changes. *Anesthesiology*. 1992; 77: 1134-42.
26. Djalali Motlagh S, Rokhtabnak F, Ghodrati MR, et al. Effect of Different Loading Doses of Dexmedetomidine on Controlled Hypotension and the Incidence of Bradycardia During Rhinoplasty: A Clinical Trial. *Anesth Pain Med*. 2021; 11: e118857.
27. Huang X, Lin D, Sun Y, et al. Effect of Dexmedetomidine on Postoperative Sleep Quality: A Systematic Review. *Drug Des Devel Ther*. 2021; 15:2161-70.
28. Gu HB, Song YA, Bai J. Median Effective Dose of Intranasal Dexmedetomidine for Transthoracic Echocardiography in Children with Kawasaki Disease Who Have a History of Repeated Sedation. *Med Sci Monit*. 2019; 25:381-8.
29. Hannivoort LN, Absalom AR, Struys MMRF, et al. The role of pharmacokinetics and pharmacodynamics in clinical anaesthesia practice. *Curr Opin Anaesthesiol*. 2020; 33:483-9.